There is growing evidence that pharmacotherapies may be effective in preventing alcohol use disorder (AUD) in people with post-traumatic stress disorder (PTSD). A review of available studies found that medications such as naltrexone, acamprosate, and disulfiram were associated with reduced drinking in people with PTSD. In addition, the anticonvulsant topiramate was found to be effective in reducing problem drinking in people with PTSD and comorbid AUD.
These findings suggest that pharmacotherapies may be a promising approach to preventing AUD in people with PTSD. However, more research is needed to confirm these findings and to determine the most effective medications and dosages.
A new study has shown that pharmacotherapies can prevent alcohol use disorder in people with PTSD. The study, which is the first of its kind, was conducted by a team of researchers at the University of Colorado Anschutz Medical Campus.
The study included a group of veterans who were diagnosed with PTSD and were receiving treatment for their condition. The group was divided into two groups, with one group receiving a pharmacotherapy treatment and the other receiving a placebo.
The study found that the group who received the pharmacotherapy treatment were less likely to develop alcohol use disorder than the group who received the placebo. The study also found that the group who received the pharmacotherapy treatment had a lower rate of relapse than the group who received the placebo.
This study is important because it is the first of its kind to show that pharmacotherapies can prevent alcohol use disorder in people with PTSD. This is a significant finding, as alcohol use disorder is a major problem for people with PTSD.
The findings of this study will help to improve the treatment of PTSD and will likely lead to the development of new and improved pharmacotherapies for the prevention of alcohol use disorder in people with PTSD.